Poxel SA   Report issue

For profit Phase 1 Phase 2
Founded: Lyon France (2009)

Organization Overview

First Clinical Trial
2013
NCT01951235
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Poxel SA

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Fatty Liver (Phase 2)

Liver Diseases (Phase 1)

Metabolic Diseases (Phase 1)

Non-alcoholic Fatty Liver Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 14
  • # of Trial APIs: 6